NUDT21 overexpression acts as a key regulator of alternative polyadenylation (APA) and exhibits oncogenic properties in prostate cancer, with its unmethylated 3′UTR shortening identified as a novel mechanism underlying enzalutamide resistance (Zhou et al., 2024; Xiao et al., 2023; Lin et al., 2024). This evidence concerns the gene NUDT21 and prostate cancer.